Stay updated with breaking news from Dermavant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.“A common question that comes up is whether the biologics that we routinely use in clinical practice, such as dupilumab, are safe in this
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.
NEW ORLEANS — Patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile, according to phase 3 study results presented here. “These results are the first to highlight how Dupixent can improve signs and symptoms of atopic hand and foot dermatitis, which is very difficult to treat,” Eric Simpson,
NEW ORLEANS — Patients with atopic dermatitis experienced a rapid and sustained reduction in itch with topical roflumilast cream treatment, according to phase 3 study results presented at the American Academy of Dermatology Annual Meeting.“The study supports that roflumilast cream 0.15% showed efficacy, good safety and very good tolerance for children and adults with atopic dermatitis
The Global Atopic Dermatitis Market Size was valued at USD 15.20 Billion in 2021 and the worldwide atopic dermatitis market size is expected to reach USD...